PET Parameters are Useful in Predicting Endometrial Cancer Risk Classes and Prognosis

Abstract

Aim We investigate the role of preoperative PET parameters to determine risk classes and prognosis of endometrial cancer (EC).

Methods We enrolled 81 patients with EC who underwent preoperative F-18 FDG PET/CT. PET parameters (SUV_max, SUV_mean, MTV, TLG), grade, histology and size of the primary tumor, stage of the disease, the degree of myometrial invasion (MI), and the presence of lymphovascular invasion (LVI), cervical invasion (CI), distant metastasis (DM) and lymph node metastasis (LNM) were recorded. The relationship between PET parameters, clinicopathological risk factors and overall survival (OS) was evaluated.

Results The present study included 81 patients with EC (mean age 60). Of the total sample, 21 patients were considered low risk (endometrioid histology, stage 1A, grade 1 or 2, tumor diameter < 4 cm, and LVI negative) and 60 were deemed high risk. All of the PET parameters were higher in the presence of a high-risk state, greater tumor size, deep MI, LVI and stage 1B-4B. MTV and TLG values were higher in the patients with non-endometrioid histology, CI, grade 3 and LNM. The optimum cut-off levels for differentiating between the high and low risk patients were: 11.1 for SUV_max (AUC = 0.757), 6 for SUV_mean (AUC = 0.750), 6.6 for MTV(AUC = 0.838) and 56.2 for TLG(AUC = 0.835). MTV and TLG values were found as independent prognostic factors for OS, whereas SUV_max and SUV_mean values were not predictive.

Conclusions The PET parameters are useful in noninvasively differentiating between risk groups of EC. Furthermore, volumetric PET parameters can be predictive for OS of EC.

Zusammenfassung

Ziel Wir untersuchen die Rolle präoperativer PET-Parameter bei der Bestimmung der Risikogruppen und der Prognose von Endometriumkarzinomen (EK).

Methoden Wir haben 81 Patienten mit EC eingeschlossen, bei denen eine präoperative F-18-FDG-PET/CT durchgeführt wurde. PET-Parameter (SUV_max, SUV_mean, MTV, TLG), Graduierung, Histologie und Größe des Primärtumors, das Erkrankungsstadium, der Grad der Myometriuminvasion (MI) und das Vorhandensein einer lymphovaskulären Invasion (LVI), einer Zervixinvasion (CI), einer Fernmetastase und einer Lymphknotenmetastase (LKM) wurden erfasst. Die Relation zwischen PET-Parametern, klinisch-pathologischen Risikofaktoren und dem Gesamtüberleben („overall survival“, OS) wurde bewertet.

Ergebnisse Die vorliegende Studie umfasste 81 Patienten mit EK (Durchschnittsalter 60). Von der Gesamtstichprobe wurden 21 Patienten als Niedrigrisiko-Gruppe (endometrioide Histologie, Stadium 1A, Grad 1 oder 2, Tumordurchmesser < 4 cm und LVI negativ) und 60 als Hochrisikogruppe eingestuft. Alle PET-Parameter waren bei Vorliegen eines Hochrisikos, größerer Tumorgröße, tieferer MI, LVI und einem Stadium 1B–4B höher. MTV- und TLG-Werte waren bei den Patientinnen mit nichtendometrioider Histologie, CI, Grad 3 und LKM höher. Die optimalen Cut-off-Werte für die Differenzierung von Patienten mit Hoch- und Niedrigrisiko betrugen für SUV_max 11,1 (AUC = 0,757), für SUV_mean 6 (AUC = 0,750), für MTV 6,6 (AUC = 0,838) und für TLG 56,2 (AUC = 0,835). MTV- und TLG-Werte waren unabhängige prognostische Faktoren für das OS, während SUV_max- und SUV_mean-Werte nicht prädiktiv waren.

Schlussfolgerungen Die PET-Parameter sind nützlich, um nichtinvasiv zwischen Risikogruppen bei EK zu unterscheiden. Darüber hinaus können die volumetrischen PET-Parameter prädiktiv für das OS bei EK sein.

Key words

endometrial cancer risk classes - FDG PET CT - SUV_max - MTV - TLG - prognosis

Schlüsselwörter

Risikogruppen bei Endometriumkarzinom - FDG-PET/CT - SUV_max - MTV - TLG, Prognose

Publikationsverlauf

Eingereicht: 04. März 2020

Angenommen: 03. September 2020

Artikel online veröffentlicht:
26. Oktober 2020

• References

• 1 Kitajima K, Suenaga Y, Ueno Y. et al. Preoperative risk stratification using metabolic parameters of F-FDG PET/CT in patients with endometrial cancer. Eur J Nucl Med Mol Imaging 2015; 42: 1268-1275
• 2 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and majör patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: 359-386
• 3 Cornelison TL, Trimble EL, Kosary CL. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988–1994. Gynecol Oncol 1999; 74: 350-355
• 4 Creutzberg CL, van Putten WL, Koper PC. et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355: 1404-1411
• 5 Colombo N, Creutzberg C, Amant F. et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer 2016; 26: 2-30
• 6 Galaal K, Al Moundhri M, Bryant A. et al. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev 2014; 5: CD010681
• 7 Di Cello A, Rania E, Zuccala V. et al. Failure to recognize preoperatively high-risk endometrial carcinoma is associated with a poor outcome. Eur J Obstet Gynecol Reprod Biol 2015; 194: 153-160
• 8 Imai K, Kato H, Katayama K. et al. A preoperative risk-scoring system to predict lymph node metastasis in endometrial cancer and stratify patients for lymphadenectomy. Gynecol Oncol 2016; 142: 273-277
• 9 Mariani A, Dowdy SC, Cliby WA. et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008; 109: 11-18
• 10 AlHilli MM, Mariani A, Bakkum-Gamez JN. et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Onco 2014; 133: 485-493
• 11 Kang S, Lee JM, Lee JK. et al. A Web-based nomogram predicting para-aortic nodal metastasis in incompletely staged patients with endometrial cancer: a Korean multicenter study. Int J Gynecol Cancer 2014; 24: 513-519
• 12 Keys HM, Roberts JA, Brunetto VL. et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol 2004; 92: 744-751
• 13 Barlin JN, Soslow RA, Lutz M. et al. Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. Int J Gynecol Cancer 2013; 23: 1620-1628
• 14 Kong TW, Chang SJ, Paek J. et al. Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the gynecologic oncology group criteria. J Gynecol Oncol 2015; 26: 32-39
• 15 Kwon JS, Qiu F, Saskin R. et al. Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer?. Obstet Gynecol 2009; 114: 736-743
• 16 Bendifallah S, Canlorbe G, Collinet P. et al. Just how accurate are the major risk stratification systems for early-stage endometrial cancer?. Br J Cancer 2015; 112: 793-801
• 17 Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract 2016; 3: 14
• 18 Haldorsen IS, Salvesen HB. Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques. Clin Radiol 2012; 67: 2-12
• 19 Haldorsen IS, Husby JA, Werner HM. et al. Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists. Eur Radiol 2012; 22: 1601-1611
• 20 Chang MC, Chen JH, Liang JA. et al. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis. Eur J Radiol 2012; 81: 3511-3517
• 21 Crivellaro C, Signorelli M, Guerra L. et al. Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT. Gynecol Oncol 2013; 130: 306-311
• 22 Horowitz NS, Dehdashti F, Herzog TJ. et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004; 95: 546-551
• 23 Suzuki R, Miyagi E, Takahashi N. et al. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer 2007; 17: 890-896
• 24 Lee HJ, Ahn BC, Hong CM. et al. Preoperative risk stratification using 18FFDG PET/CT in women with endometrial cancer. Nuklearmedizin 2011; 50: 204-213
• 25 Shim SH, Kim DY, Lee DY. et al. Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer. BJOG 2014; 121: 1097-1106
• 26 Walentowicz-Sadlecka M, Malkowski B, Walentowicz P. et al. The preoperative maximum standardized uptake value measured by 18F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients. Biomed Res Int 2014; 2014: 234813
• 27 Antonsen SL, Loft A, Fisker R. et al. SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients. Gynecol Oncol 2013; 129: 298-303
• 28 Akin EA, Kuhl ES, Zeman RK. The role of FDG-PET/CT in gynecologic imaging: an updated guide to interpretation and challenges. Abdom Radiol 2018; 43: 2474-2486
• 29 NCCN Practice Guidelines Narrative Summary of Indications for FDG PET and PET/ CT. 2/14/2016 ed2016.
• 30 Boellaard R, O'Doherty MJ, Weber WA. et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200
• 31 Colombo N, Creutzberg C, Amant F. et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016; 27: 16-41
• 32 Kitajima K, Kita M, Suzuki K. et al. Prognostic significance of SUVmax (maximum standardized uptake value) measured by [(1)(8)F] FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging 2012; 39: 840-845
• 33 Nakamura K, Kodama J, Okumura Y. et al. The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer. Int J Gynecol Cancer 2010; 20: 110-115
• 34 Torizuka T, Nakamura F, Takekuma M. et al. FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nucl Med Commun 2006; 27: 481-487
• 35 Ghooshkhanei H, Treglia G, Sabouri G. et al. Risk stratification and prognosis determination using (18)F-FDG PET imaging in endometrial cancer patients: a systematic review and meta-analysis. Gynecol Oncol 2014; 132: 669-676
• 36 Husby JA, Reitan BC, Biermann M. et al. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients. J Nucl Med 2015; 56: 1191-1198
• 37 Adams MC, Turkington TG, Wilson JM. et al. A systematic review of the factors affecting accuracy of SUV measurements. Am J Roentgenol 2010; 195: 310-320
• 38 Brendle C, Kupferschläger J, Nikolaou K. et al. Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? – Variability induced by different SUV measurements and varying reconstruction methods. Eur J Radiol 2015; 84: 158-162
• 39 Sher A, Lacoeuille F, Fosse P. et al. For avid glucose tumors, the SUV peak is the most reliable parameter for [(18)F]FDG-PET/CT quantification, regardless of acquisition time. EJNMMI Res 2016; 6: 21
• 40 Ziai P, Hayeri MR, Salei A. et al. Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology. Radiographics 2016; 36: 481-496
• 41 Lee HY, Hyun SH, Lee KS. et al. Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 2010; 17: 2787-2794